Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Mario Hasler
  • Richardus Vonk
  • Ludwig A. Hothorn

Research Organisations

External Research Organisations

  • Bayer Pharma AG
View graph of relations

Details

Original languageEnglish
Pages (from-to)490-503
Number of pages14
JournalStatistics in medicine
Volume27
Issue number4
Publication statusPublished - 12 Sept 2007

Abstract

In this paper, we describe an adjusted method to facilitate non-inferiority tests in a three-arm design. While the methodology is readily available in the situation of homogeneous group variances, the adjusted method will also maintain the α-level in the presence of heteroscedasticity. We propose explicit criteria for an optimal allocation. Depending on the pattern of heterogeneity, remarkably unbalanced designs are power optimal. We will apply the method to a randomized clinical trial and a toxicological experiment.

Keywords

    Fieller's condifence interval, Heteroscedasticity, Non-inferiority, Optimal allocation, Three-arm trial

ASJC Scopus subject areas

Cite this

Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity. / Hasler, Mario; Vonk, Richardus; Hothorn, Ludwig A.
In: Statistics in medicine, Vol. 27, No. 4, 12.09.2007, p. 490-503.

Research output: Contribution to journalArticleResearchpeer review

Hasler, Mario ; Vonk, Richardus ; Hothorn, Ludwig A. / Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity. In: Statistics in medicine. 2007 ; Vol. 27, No. 4. pp. 490-503.
Download
@article{a0b0673571a74f74937a869fa2be17ff,
title = "Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity",
abstract = "In this paper, we describe an adjusted method to facilitate non-inferiority tests in a three-arm design. While the methodology is readily available in the situation of homogeneous group variances, the adjusted method will also maintain the α-level in the presence of heteroscedasticity. We propose explicit criteria for an optimal allocation. Depending on the pattern of heterogeneity, remarkably unbalanced designs are power optimal. We will apply the method to a randomized clinical trial and a toxicological experiment.",
keywords = "Fieller's condifence interval, Heteroscedasticity, Non-inferiority, Optimal allocation, Three-arm trial",
author = "Mario Hasler and Richardus Vonk and Hothorn, {Ludwig A.}",
year = "2007",
month = sep,
day = "12",
doi = "10.1002/sim.3052",
language = "English",
volume = "27",
pages = "490--503",
journal = "Statistics in medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

Download

TY - JOUR

T1 - Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity

AU - Hasler, Mario

AU - Vonk, Richardus

AU - Hothorn, Ludwig A.

PY - 2007/9/12

Y1 - 2007/9/12

N2 - In this paper, we describe an adjusted method to facilitate non-inferiority tests in a three-arm design. While the methodology is readily available in the situation of homogeneous group variances, the adjusted method will also maintain the α-level in the presence of heteroscedasticity. We propose explicit criteria for an optimal allocation. Depending on the pattern of heterogeneity, remarkably unbalanced designs are power optimal. We will apply the method to a randomized clinical trial and a toxicological experiment.

AB - In this paper, we describe an adjusted method to facilitate non-inferiority tests in a three-arm design. While the methodology is readily available in the situation of homogeneous group variances, the adjusted method will also maintain the α-level in the presence of heteroscedasticity. We propose explicit criteria for an optimal allocation. Depending on the pattern of heterogeneity, remarkably unbalanced designs are power optimal. We will apply the method to a randomized clinical trial and a toxicological experiment.

KW - Fieller's condifence interval

KW - Heteroscedasticity

KW - Non-inferiority

KW - Optimal allocation

KW - Three-arm trial

UR - http://www.scopus.com/inward/record.url?scp=39449129871&partnerID=8YFLogxK

U2 - 10.1002/sim.3052

DO - 10.1002/sim.3052

M3 - Article

C2 - 17853384

AN - SCOPUS:39449129871

VL - 27

SP - 490

EP - 503

JO - Statistics in medicine

JF - Statistics in medicine

SN - 0277-6715

IS - 4

ER -